BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Direct Healthcare Professional Communication (DHPC) on Cytotec® (misoprostol): risks associated with an off-label use for birth initiation

2020.03.16

Active substance: Misoprostol

The German Federal Institute for Drugs and Medical Devices (BfArM) informs that there are numerous new reports of severe side effects when using Cytotec® outside the approved indication. The drug Cytotec® is not approved for birth initiation.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 235KB, File is accessible